Uniqure (NASDAQ:QURE) received a $48.00 target price from equities research analysts at HC Wainwright in a report issued on Friday, October 19th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 87.50% from the stock’s current price.
Several other equities research analysts have also recently commented on the company. BidaskClub cut Uniqure from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. B. Riley assumed coverage on Uniqure in a research report on Wednesday, June 27th. They set a “buy” rating and a $50.00 price objective on the stock. Cantor Fitzgerald set a $58.00 target price on Uniqure and gave the company a “buy” rating in a report on Saturday, August 11th. Zacks Investment Research downgraded Uniqure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 25th. Finally, Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Uniqure in a report on Thursday, October 18th. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Uniqure currently has an average rating of “Buy” and an average target price of $44.90.
Shares of Uniqure stock traded down $0.42 during midday trading on Friday, reaching $25.60. 193,722 shares of the company’s stock traded hands, compared to its average volume of 343,597. The company has a market cap of $969.32 million, a PE ratio of -8.71 and a beta of 0.78. Uniqure has a 12 month low of $13.71 and a 12 month high of $43.23. The company has a quick ratio of 8.36, a current ratio of 8.36 and a debt-to-equity ratio of 0.06.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.04. The company had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.37 million. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. On average, research analysts anticipate that Uniqure will post -2.44 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in QURE. California Public Employees Retirement System purchased a new position in shares of Uniqure in the 1st quarter worth approximately $332,000. Jane Street Group LLC purchased a new position in shares of Uniqure in the 1st quarter worth approximately $224,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Uniqure by 276.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 4,700 shares during the period. Millennium Management LLC lifted its stake in shares of Uniqure by 242.8% during the 1st quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after acquiring an additional 538,031 shares during the last quarter. Finally, Financial Gravity Wealth Inc. bought a new stake in shares of Uniqure during the 1st quarter worth approximately $177,000. Hedge funds and other institutional investors own 59.10% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Further Reading: Calculate Your Return on Investment (ROI)